These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 15868426)

  • 21. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer.
    Götte M; Kersting C; Ruggiero M; Tio J; Tulusan AH; Kiesel L; Wülfing P
    Anticancer Res; 2006; 26(1B):621-7. PubMed ID: 16739330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer.
    Pickles MD; Gibbs P; Lowry M; Turnbull LW
    Magn Reson Imaging; 2006 Sep; 24(7):843-7. PubMed ID: 16916701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic breast magnetic resonance imaging: pretreatment prediction of tumor response to neoadjuvant chemotherapy.
    Dongfeng H; Daqing M; Erhu J
    Clin Breast Cancer; 2012 Apr; 12(2):94-101. PubMed ID: 22169574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer.
    Soliman H; Gunasekara A; Rycroft M; Zubovits J; Dent R; Spayne J; Yaffe MJ; Czarnota GJ
    Clin Cancer Res; 2010 May; 16(9):2605-14. PubMed ID: 20406836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
    Demartini WB; Lehman CD; Peacock S; Russell MT
    Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer.
    Schrier BP; Peters M; Barentsz JO; Witjes JA
    Eur Urol; 2006 Apr; 49(4):698-703. PubMed ID: 16464531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
    Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
    Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Tsunoda-Shimizu H; Hayashi N; Hamaoka T; Kawasaki T; Tsugawa K; Yagata H; Kikuchi M; Suzuki K; Nakamura S
    Breast Cancer; 2008; 15(2):133-40. PubMed ID: 18288570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast.
    Drew PJ; Kerin MJ; Mahapatra T; Malone C; Monson JR; Turnbull LW; Fox JN
    Eur J Surg Oncol; 2001 Nov; 27(7):617-20. PubMed ID: 11669587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast conservation after neoadjuvant chemotherapy for stage II carcinoma of the breast.
    Schwartz GF; Meltzer AJ; Lucarelli EA; Cantor JP; Curcillo PG
    J Am Coll Surg; 2005 Sep; 201(3):327-34. PubMed ID: 16125064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
    Chen H; Liang C; Zhang L; Huang S; Wu X
    Gynecol Oncol; 2008 Sep; 110(3):308-15. PubMed ID: 18606439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy in stage III breast cancer.
    Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
    Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
    Denis F; Desbiez-Bourcier AV; Chapiron C; Arbion F; Body G; Brunereau L
    Eur J Surg Oncol; 2004 Dec; 30(10):1069-76. PubMed ID: 15522553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
    Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of magnetic resonance imaging in the pre and postchemotherapy evaluation in locally advanced breast carcinoma.
    Belli P; Romani M; Costantini M; Magistrelli A; Terribile D; Nardone L; Pastore G
    Rays; 2002; 27(4):279-90. PubMed ID: 12696290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.
    Jensen LR; Garzon B; Heldahl MG; Bathen TF; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2011 Nov; 34(5):1099-109. PubMed ID: 22002757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of pretreatment dynamic contrast-enhanced MR imaging in breast cancer patients receiving neoadjuvant chemotherapy: overall survival predicted from combined time course and volume analysis.
    Heldahl MG; Bathen TF; Rydland J; Kvistad KA; Lundgren S; Gribbestad IS; Goa PE
    Acta Radiol; 2010 Jul; 51(6):604-12. PubMed ID: 20429756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.